Benign intracranial hypertension associated with the withdrawal of a non-ergot dopamine agonist.
The cases are reported of two patients who developed benign intracranial hypertension after the withdrawal of the novel non-ergot derived dopamine agonist CV 205 502 (quinagolide).
Atkin
S L
SL
Department of Endocrinology, Royal Liverpool Hospital, UK.
Masson
E A
EA
Blumhardt
L D
LD
White
M C
MC
D000328:Adult; D000634:Aminoquinolines / Q000009:adverse effects* / Q000494:pharmacology; D002560:Cerebrovascular Circulation / Q000187:drug effects; D015259:Dopamine Agents / Q000009:adverse effects*; D005260:Female; D006801:Humans; D006966:Hyperprolactinemia / Q000188:drug therapy; D008881:Migraine Disorders / Q000517:prevention & control; D011559:Pseudotumor Cerebri / Q000139:chemically induced*; D013375:Substance Withdrawal Syndrome / Q000209:etiology*
D000634:Aminoquinolines; D015259:Dopamine Agents; C046650:quinagolide